logo
Sign in

BVS Stock Price, Chart, Stats & News

Bioventus Inc
Save

Bioventus Inc (BVS) does not currently pay a dividend.

639.54M
Market cap
12.59x
Current P/E
12.63x
Forward P/E

BVS chart

1M
3M
1Y
5Y
Loading chart...

Fundamentals

Gross margin
67.32%
Operating margin
10.04%
Pretax margin
4.53%
Net margin
4.00%
Effective tax rate
-6.09%
ROA
3.33%
ROE
13.79%
D/E
1.69x
Interest coverage ratio
2.15x

BVS valuation

P/E
12.59x
P/S
1.06x
P/B
3.24x
P/CF
7.98x
P/FCF
8.35x
P/OCF
7.98x
PEG
0.14x
EV multiple
3.24x

About

Bioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally. The company’s product portfolio includes pain treatments, which comprise various intra-articular and hyaluronic acid injections; peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis; and Stimrouter to treat chronic peripheral pain, and TalisMann provides stimulation to the targeted peripheral nerve, as well as XCELL PRP System, a benchtop device that processes whole blood to produce high-yield PRP with a 10-minute single-spin cycle. It also offers precision bone resection for patients with degenerative spine conditions and spinal deformities, as well as enables precision ultrasonic neuro and general surgery to address brain tumors and pathologies of the liver and other organs; and bone graft substitutes, including various products that facilitate optimal bone fusion.

Similar securities

Based on sector and market capitalization

Report issue